WT1 peptide vaccination treatment for leukaemia: a phase I/II safety and toxicity study (WTPV-001)

Trial Profile

WT1 peptide vaccination treatment for leukaemia: a phase I/II safety and toxicity study (WTPV-001)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2006

At a glance

  • Drugs INNO 305 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms WTPV
  • Most Recent Events

    • 08 Sep 2006 The expected completion date for this trial is now 1 May 2007.
    • 08 Sep 2006 Status change
    • 08 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top